AI Pathology Platform Tapped to Decode Tumor Secrets in 17-Trial Cancer Drug Program
Summit Therapeutics partners with Lunit to apply computational pathology across its massive ivonescimab clinical portfolio, signaling AI's growing role in late-stage drug development.
Summit Therapeutics and Lunit have forged a research collaboration that positions artificial intelligence as a core analytical tool across one of oncology's largest active clinical programs. Announced October 24, 2026, the partnership will deploy Lunit's AI-powered pathology platform, Lunit SCOPE IO, to analyze tumor microenvironment characteristics in tissue samples from Summit's ivonescimab trials—a sprawling effort encompassing 17 Phase III studies across multiple cancer types.
Ivonescimab, an investigational bispecific antibody targeting both PD-1 and VEGF in a single molecule, has already reported five positive Phase III readouts in non-small cell lung cancer (NSCLC) and biliary tract cancer. The drug remains investigational and has not been approved by regulatory authorities in Summit's licensed territories, which include the United States and Europe.
AI Meets Immuno-Oncology at Scale
Lunit SCOPE IO analyzes standard hematoxylin and eosin (H&E) whole-slide images—the ubiquitous tissue staining method used in pathology labs worldwide—to identify features of the tumor microenvironment without requiring additional specialized staining or assays. This computational approach offers a potentially scalable method for biomarker discovery and patient stratification across Summit's extensive clinical portfolio, which includes five global trials sponsored by Summit and active studies in NSCLC, colorectal cancer, and urothelial carcinoma.
According to Allen Yang, MD, PhD, Summit's Chief Research and Development Strategy Officer, the collaboration aims to leverage AI-driven insights from tissue samples already collected in ivonescimab trials. Brandon Suh, CEO of Lunit, emphasized the partnership's potential to advance understanding of how bispecific mechanisms operate within complex tumor environments.
Ivonescimab, developed by Akeso Inc., exhibits what Summit describes as "multifold higher affinity to PD-1 when in the presence of VEGF," a binding characteristic that distinguishes it from single-target checkpoint inhibitors. The drug's dual mechanism has driven interest in understanding how tumor microenvironment features correlate with clinical outcomes—precisely the question Lunit's platform is designed to address.
Computational Pathology as Drug Development Infrastructure
The collaboration represents a broader trend: AI pathology platforms transitioning from research tools to essential infrastructure in biopharma drug development. For Lunit, partnering with a company running 17 Phase III trials validates the commercial and scientific value of computational pathology in late-stage oncology programs, potentially positioning the company competitively against digital pathology rivals in the biopharma services market.
For oncology drug developers, the partnership exemplifies how AI-driven analysis can be integrated into existing clinical workflows without requiring new tissue collection protocols or specialized assays—a practical advantage in large, multi-site international trials.
Lunit SCOPE products are designated for research purposes only and are "not for use in diagnostic procedures or decisions." No clinical outcome data was released in conjunction with this collaboration announcement.
What This Means for Cancer Care
While ivonescimab remains investigational, this research may inform future patient selection strategies for bispecific immuno-oncology therapies. If regulatory approval is achieved and AI-derived biomarkers prove clinically meaningful, computational pathology could help match patients to treatments more effectively in NSCLC, colorectal, biliary tract, and urothelial cancers—conditions currently addressed by Summit's active trial portfolio.
The partnership signals that computational pathology is becoming standard practice in next-generation immuno-oncology development, potentially accelerating the path from drug candidate to precision medicine application.
Correction, October 25, 2026: An earlier version of this article gave the year of the Summit–Lunit announcement as 2024. The correct year is 2026.
Sources
Companies in this article
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.